专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20100055129A1 MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF INDENTIFIYING AGENTS THAT MODULATE MYC 有权
标题翻译： MYC的调节器，使用该方法的方法以及调整MYC的代理方法
公开(公告)号：US20100055129A1
公开(公告)日：2010-03-04
申请号：US12550166
申请日：2009-08-28
申请人： Yosef Refaeli , Brian Curtis Turner
发明人： Yosef Refaeli , Brian Curtis Turner
IPC分类号： A61K39/145 , C07K14/00 , A61K47/06 , A61K39/00 , A61K39/29 , A61P37/04 , A61K39/13 , A61K39/165 , A61K39/20 , A61K39/05 , A61K39/10 , A61K39/25 , A61K39/15 , A61K39/095 , A61K39/108 , A61K39/275 , A61K39/106 , A61K39/12 , A61K39/04
CPC分类号： A61K39/39 , A61K38/00 , C07K14/001 , C07K14/47 , C07K14/82 , C07K2319/02 , C07K2319/21 , Y02A50/387 , Y02A50/406 , Y02A50/463 , Y02A50/465 , Y02A50/471
摘要： Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
摘要翻译：本文公开了调节细胞存活力的方法。本文进一步公开的是调节免疫应答的方法。本文进一步公开的是识别能够调节细胞活力或免疫应答的试剂的方法。本文进一步公开的是能够调节细胞活力或免疫应答的试剂和组合物。

72. 发明申请

US20090074816A1 TISSUE TARGETED ANTIGENIC ACTIVATION OF THE IMMUNE RESPONSE TO CANCERS 有权
标题翻译：针对癌症的免疫应答组织针对性抗原激活
公开(公告)号：US20090074816A1
公开(公告)日：2009-03-19
申请号：US12234569
申请日：2008-09-19
申请人： Harold David Gunn
发明人： Harold David Gunn
IPC分类号： A61K39/165 , A61K39/05 , A61K39/07 , A61K39/085 , A61K39/104 , A61K39/108 , A61K39/20 , A61K39/245 , A61K39/29 , A61P35/00 , A61K39/285 , A61K39/205 , A61K39/02 , A61K39/12 , A61K39/125 , A61K39/145 , A61K39/155
CPC分类号： A61K39/0011 , A61K2039/521 , A61K2039/5252 , A61K2300/00
摘要： The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of a treatment response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent visible delayed inflammatory immune reaction at the successive site or sites of administration.
摘要翻译：本发明部分地通过给予在癌症所在的特定器官或组织中具有致病性的一种或多种微生物具有抗原性特异性的组合物来治疗特定器官或组织的癌症的方法。因此，本发明的制剂有助于激活对特定组织或器官中的癌症的治疗反应。组合物可以例如包括杀死或减毒的微生物病原体，并且可以在远离癌症的位置（例如皮肤）施用。在一些实施方案中，已知在相关器官或组织中引起感染的内源性菌群的微生物物种可用于抗原组合物的制剂中。在替代实施方案中，已知在相关器官或组织中引起感染的外源微生物病原体可用于抗原组合物的制剂中。免疫原性组合物的施用可以在相当长的时间内相对频繁地重复。在皮内注射或皮下注射的实施方案中，可以调节剂量，使得注射在连续的施用部位或再现部位再现一致的可见延迟炎症免疫反应。

73. 发明申请

US20090010964A1 Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines 审中-公开
标题翻译：脂质和一氧化二氮组合作为提高疫苗功效的佐剂
公开(公告)号：US20090010964A1
公开(公告)日：2009-01-08
申请号：US11794503
申请日：2006-08-03
申请人： Anne Grobler , Abraham Frederik Kotze
发明人： Anne Grobler , Abraham Frederik Kotze
IPC分类号： A61K39/145 , A61K39/00 , A61K39/12 , A61K39/02 , A61K39/07 , A61K39/106 , A61K39/102 , A61K39/095 , A61K39/13 , A61P37/02 , A61K47/12 , A61K39/25 , A61K39/20 , A61K39/205 , A61K39/165 , A61K39/10 , A61K39/09 , A61K39/08 , A61K39/112 , A61K39/05 , A61K39/29
CPC分类号： A61K39/39 , A61K39/05 , A61K39/205 , A61K39/292 , A61K2039/55544 , A61K2039/55555 , Y02A50/388 , Y02A50/396 , Y02A50/466 , Y02A50/484
摘要： The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], decosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.
摘要翻译：本发明提供增强对疫苗制剂中的抗原的免疫应答的方法，以及提供对抗原的增强的免疫应答的疫苗制剂。在该方法和制剂中，抗原与佐剂一起施用，所述佐剂包含一氧化二氮气体在用于气体的药学上可接受的载体溶剂中的溶液，并且该佐剂包括至少一种脂肪酸或酯或选自下组的其它合适的衍生物由油酸，亚油酸，α-亚麻酸，γ-亚麻酸，花生四烯酸，二十碳五烯酸[C20：5omega3]，十二碳六烯酸[C22：6omega3]，蓖麻油酸及其衍生物组成，选自C1 其C6烷基酯，其甘油 - 聚乙二醇酯和主要由蓖麻油酸基油如蓖麻油与环氧乙烷组成的氢化天然油的反应产物。

74. 发明授权

US07438914B2 Composition and method for enhancing immune response 失效
标题翻译：用于增强免疫应答的组合物和方法
公开(公告)号：US07438914B2
公开(公告)日：2008-10-21
申请号：US10506796
申请日：2003-03-06
申请人： Tsafrir S. Mor , Nobuyuki Matoba , Charles J. Arntzen
发明人： Tsafrir S. Mor , Nobuyuki Matoba , Charles J. Arntzen
IPC分类号： A61K38/16 , A61K38/31 , A61K39/02 , A61K39/20 , A61K35/00 , A61K39/16 , C12N15/00
CPC分类号： C07K14/005 , A61K39/39 , A61K2039/541 , A61K2039/55516 , A61K2039/6037 , A61K2039/6075 , C12N2740/16122
摘要： A composition and method for enhancing immune response in a living organism is disclosed. In particular, the present disclosure provides an adjuvant peptide for use in raising an immune response to an antigen. The adjuvant peptide is selected from a group of peptides with an HIV-related sequence. Additionally, the adjuvant peptide can comprise a fusion-protein that acts as a mucosal adjuvant. The adjuvant peptide can be transformed into one or more living cells, such that the mucosal adjuvant can be produced in living cells and then administered by systemic, mucosal or epidermal delivery.
摘要翻译：公开了一种增强活体内免疫应答的组合物和方法。特别地，本公开提供了用于提高对抗原的免疫应答的佐剂肽。佐剂肽选自具有HIV相关序列的肽组。另外，佐剂肽可以包含充当粘膜佐剂的融合蛋白。辅助肽可以转化成一个或多个活细胞，使得粘膜佐剂可以在活细胞中产生，然后通过全身，粘膜或表皮递送进行施用。

75. 发明授权

US07101553B2 Immune response enhancement methods 失效
标题翻译：免疫反应增强方法
公开(公告)号：US07101553B2
公开(公告)日：2006-09-05
申请号：US10822799
申请日：2004-04-13
申请人： Ferdinand Haschke , Anne-Lise Carrie , Zdenek Kratky , Harriet Link-Amster , Florence Rochat
发明人： Ferdinand Haschke , Anne-Lise Carrie , Zdenek Kratky , Harriet Link-Amster , Florence Rochat
IPC分类号： A61K39/165 , A61K39/20
CPC分类号： A61K31/733
摘要： A prebiotic for enhancement of an immune response, a nutritional composition for enhancement of an immune response; use of a prebiotic in the manufacture of a medicament or nutritional composition for enhancement of an immune response; use of a prebiotic in the manufacture of a medicament or nutritional composition for the prevention or treatment of measles; a method of enhancing an immune response which comprises administering an effective amount of a prebiotic; and a method of prevention or treatment of measles which comprises administering an effective amount of a prebiotic. In preferred embodiments the prebiotic comprises a fructo-oligosaccharide.
摘要翻译：用于增强免疫应答的益生元，用于增强免疫应答的营养组合物; 在制备用于增强免疫应答的药物或营养组合物中使用益生元; 使用益生元制造用于预防或治疗麻疹的药物或营养组合物; 一种增强免疫应答的方法，其包括施用有效量的益生元; 以及预防或治疗麻疹的方法，其包括施用有效量的益生元。在优选的实施方案中，益生元包括低聚果糖。

76. 发明授权

US5169784A Baculovirus dual promoter expression vector 失效
标题翻译： BACULOVIRUS双重促进剂表达载体
公开(公告)号：US5169784A
公开(公告)日：1992-12-08
申请号：US583392
申请日：1990-09-17
申请人： Max D. Summers , Christian E. G. Oker-Blom
发明人： Max D. Summers , Christian E. G. Oker-Blom
IPC分类号： A61K39/00 , A61K39/20 , C07K14/18 , C07K14/19 , C12N7/00 , C12N15/09 , C12N15/40 , C12N15/86 , C12N15/866
CPC分类号： C12N15/86 , C07K14/005 , C12N7/00 , A61K39/00 , C12N2710/14121 , C12N2710/14143 , C12N2710/14144 , C12N2770/36122 , C12N2770/36143 , C12N2770/36222
摘要： This invention relates to specifically designing and genetically engineering recombinant baculovirus for producing, in a compatible insect system, a desired protein, virus, protein hybrid, or virus hybrid. In particular aspects, this invention relates to the use of different baculovirus promoters for the ultimate purpose of constructing a recombinant baculovirus designed for the investigator's specific need. For example, the recombinant baculovirus of this invention can be designed to produce a viral pesticide.This invention also describes the construction of a genetically engineered virus or virus hybrid (e.g. animal or human pathogen) which is not capable of replicating itself but is essentially identical to the authentic pathogen in terms of structure and antigenicity. This baculovirus is constructed such that the non-structural viral genes are truncated, mutated or both and are located 3' and directly under the control of an early baculovirus gene promoter and the structural viral genes are located 3' and directly under the control of a late baculovirus gene promoter. This genetically engineered baculovirus is therefore capable of temporal regulation and successive synthesis of non-structural and structural proteins. The truncated or mutated non-structural viral genes creates the non-replicative aspect of this invention. Since the genetically produced virus or virus hybrid is essentially identical to the authentic pathogen, the product is thereby highly antigenic and potent in terms of efficacy and efficiency. This invention enables the design and constructure of a virus particle or virus hybrid with specific antigenic properties which further allows for the safe and inexpensive production of vaccines or diagnostics.
摘要翻译：本发明涉及专门设计和遗传工程重组杆状病毒，用于在相容的昆虫系统中产生所需的蛋白质，病毒，蛋白质杂种或病毒杂交体。在具体方面，本发明涉及不同杆状病毒启动子用于构建针对研究者特定需要而设计的重组杆状病毒的最终目的。例如，本发明的重组杆状病毒可被设计成生产病毒性农药。本发明还描述了在结构和抗原性方面不能复制自身但与真实病原体基本相同的遗传工程病毒或病毒杂交体（例如动物或人类病原体）的构建。构建这种杆状病毒使得非结构病毒基因被截短，突变或两者并且位于3'并且直接在早期杆状病毒基因启动子的控制下，并且结构病毒基因位于3'并且直接在a 晚期杆状病毒基因启动子。因此，这种基因工程的杆状病毒能够进行非结构和结构蛋白质的时间调节和连续合成。截短或突变的非结构病毒基因产生本发明的非复制方面。由于遗传产生的病毒或病毒杂合物与真实病原体基本上相同，因此产品在功效和效率方面具有高度的抗原性和有效性。本发明使得具有特定抗原性质的病毒颗粒或病毒杂交体的设计和结构进一步允许安全和廉价地生产疫苗或诊断。

77. 发明授权

US5164481A Peptides and analogues and mixtures thereof for detecting and eliciting antibodies to rubella virus 失效
标题翻译：用于检测和预防抗生素对RUBELLA病毒的肽和类似物及其混合物
公开(公告)号：US5164481A
公开(公告)日：1992-11-17
申请号：US397767
申请日：1989-08-23
申请人： Martial Lacroix , Maan Zrein , Gervais Dionne
发明人： Martial Lacroix , Maan Zrein , Gervais Dionne
IPC分类号： A61K39/00 , A61K38/00 , A61K39/20 , A61K39/395 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/19 , C07K16/00 , C07K16/10 , C12N15/40 , C12P21/08 , G01N33/569 , G01N33/577
CPC分类号： C07K14/005 , C07K16/10 , A61K38/00 , A61K39/00 , C12N2770/36222
摘要： Linear and cyclic peptides of the E1 and C protein of the rubella virus are disclosed. These peptides and analogues, mixtures and combinations of them are useful in detecting and quantifying antibodies raised against the rubella virus. They are also useful in raising antibodies to the rubella virus for use in the diagnosis of and protection against rubella viral infections.
摘要翻译：公开了风疹病毒的E1和C蛋白的线性和环肽。这些肽及其类似物，它们的混合物和组合可用于检测和定量针对风疹病毒的抗体。它们也可用于提高风疹病毒的抗体，以用于诊断和保护风疹病毒感染。

78. 发明授权

US4195074A Process for producing a soluble rubella antigen 失效
标题翻译：生产可溶性风疹抗原的方法
公开(公告)号：US4195074A
公开(公告)日：1980-03-25
申请号：US873940
申请日：1978-01-31
申请人： John W. Safford, Jr.
发明人： John W. Safford, Jr.
IPC分类号： A61K39/20 , G01N33/569 , C12K1/04 , C12K7/00 , G01N33/16
CPC分类号： A61K39/20 , A61K39/12 , G01N33/56983 , C12N2770/36234 , Y10S436/811 , Y10S530/806 , Y10S530/81 , Y10S530/826
摘要： Purified soluble antigen, specific for rubella virus, is isolated from growth media of rubella-infected cell cultures by affinity and gel permeation chromatography and characterized, inter alia, by its specific activity. Antigen-sensitized particles are employed as immunoassay reagents in, for example, agglutination assays for detection and quantification of rubella antibodies in body fluids such as serum, spinal fluid and the like.
摘要翻译：通过亲和和凝胶渗透色谱从风疹感染的细胞培养物的生长培养基中分离纯化的风疹病毒特异性可溶性抗原，特别是通过其比活性来表征。抗原敏化颗粒用作例如用于检测和定量体液如血清，脊髓液等中的风疹抗体的凝集测定的免疫测定试剂。

79. 发明公开

US20240254515A1 FLEXIBLE EXPRESSION VECTOR SYSTEMS AND APPLICATION OF SAME TO VACCINES AND IMMUNOTHERAPEUTICS 审中-公开
公开(公告)号：US20240254515A1
公开(公告)日：2024-08-01
申请号：US18564149
申请日：2022-05-26
申请人： The University Of British Columbia , The James Hutton Institute
发明人： Wilfred A. JEFFERIES , Paolo RIBECA
IPC分类号： C12N15/86 , A61K39/00 , A61K39/20 , A61K39/215 , A61K48/00 , A61P31/14 , A61P37/04
CPC分类号： C12N15/86 , A61K39/20 , A61K39/215 , A61K48/005 , A61P31/14 , A61P37/04 , A61K2039/53 , A61K2039/55555 , A61K2039/575 , C12N2770/20043 , C12N2770/20044 , C12N2770/36143 , C12N2770/36144 , C12N2770/36244
摘要： The present invention relates to an expression vector that encodes all or a portion of replicon proteins from a positive stranded virus, wherein expression of the replicon proteins is under the control of CMV and T7 promoters, and wherein expression of a payload is under the control of a sub-genomic promoter. Also provided are methods of using the vector in therapeutics and vaccines.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式